Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Tyra Biosciences has raised $400.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2026.
Tyra Biosciences's investors include RA Capital Management, Invus, TCG Crossover, Cormorant Asset Management, Janus Henderson Investors.
Tyra Biosciences is headquartered in Carlsbad, United States.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Tyra Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tyra Biosciences — Funding & Investors." VCBacked, September 14, 2026, https://www.vcbacked.co/company/tyra-biosciences. Accessed October 16, 2026.
VCBacked. (2026). Tyra Biosciences — Funding & Investors. Retrieved October 16, 2026, from https://www.vcbacked.co/company/tyra-biosciences
{{cite web |title=Tyra Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/tyra-biosciences |website=VCBacked |access-date=October 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated